Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C21H29N3O
CAS Number:
Molecular Weight:
339.47
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
InChI
1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)
SMILES string
CC(C)N(CCC(C(N)=O)(c1ccccc1)c2ccccn2)C(C)C
InChI key
UVTNFZQICZKOEM-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
disopyramide
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
Gene Information
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Disopyramide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Biochem/physiol Actions
Class IA antiarrhythmic; sodium channel blocker
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Repr. 2
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
J P Fauchier et al.
Archives des maladies du coeur et des vaisseaux, 84(4), 553-560 (1991-04-01)
Moricizine chlorhydrate (Ethmozine), a relatively unknown antiarrhythmic agent in France, is a derivative of Phenothiazine, related to the Vaughan-Williams Class IB drugs. A randomised, double-blind, crossover trial with Disopyramide 600 mg/day after a placebo period in 10 patients with ventricular
Procainamide and disopyramide.
C Ribeiro et al.
European heart journal, 8 Suppl A, 11-19 (1987-03-01)
Pharmacokinetics and pharmacodynamics of disopyramide.
J Bonde
Danish medical bulletin, 38(2), 121-133 (1991-04-01)
T Tokudome et al.
Angiology, 50(4), 331-335 (1999-05-04)
The effect of intravenous administration of disopyramide (total dose 100 mg, bolus 20 mg every 5 minutes) was compared with that of propranolol (total dose 10 mg, bolus 2 mg every 5 minutes) in a patient with hypertrophic obstructive cardiomyopathy.
M S Croxson et al.
The New Zealand medical journal, 100(827), 407-408 (1987-07-08)
A patient treated with disopyramide presented with hypoglycaemia, a raised serum insulin level and died of pneumonia. From these findings and a review of 10 case reports, we propose that disopyramide causes hypoglycaemia by stimulation of insulin release as described
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service